Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
magrolimab (ONO-7913)
i
Other names:
ONO-7913, GS-4721, Hu5F9 G4, Hu5F9G4, 5F9, Hu5F9-G4, GS 4721, GS4721, ONO 7913, ONO7913
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(8)
News
Trials
Company:
Gilead, Ono Pharma
Drug class:
CD47 inhibitor
Related drugs:
‹
D3L-001 (7)
ALX148 (4)
VBI-003 (2)
YH38560 (2)
IMM0306 (2)
ABBV-IMAB-TJC4 (2)
AK117 (2)
RRx-001 (2)
SRF231 (2)
IMM2902 (1)
NI-2901 (1)
PT217 (1)
VBI-002 (1)
6MW3211 (0)
ADG153 (0)
AO-176 (0)
AU7R-104 (0)
CC-90002 (0)
DSP-107 (0)
HCB101 (0)
HX-009 (0)
IMC-201 (0)
IMC002 (0)
IMM2505 (0)
IMM2520 (0)
ISB 1442 (0)
JMT601 (0)
KJ-101 (0)
LB101 (0)
NI-1801 (0)
NI-2601 (0)
PF-07257876 (0)
PT886 (0)
SCR9168 (0)
SG1906 (0)
SG2501 (0)
SL-172154 (0)
TG-1801 (0)
ZL-1201 (0)
anti-CD47 monoclonal antibody (0)
IBI188 (0)
TTI-622 (0)
PF-07901800 (0)
IBI-322 (0)
IMM01 (0)
D3L-001 (7)
ALX148 (4)
VBI-003 (2)
YH38560 (2)
IMM0306 (2)
ABBV-IMAB-TJC4 (2)
AK117 (2)
RRx-001 (2)
SRF231 (2)
IMM2902 (1)
NI-2901 (1)
PT217 (1)
VBI-002 (1)
6MW3211 (0)
ADG153 (0)
AO-176 (0)
AU7R-104 (0)
CC-90002 (0)
DSP-107 (0)
HCB101 (0)
HX-009 (0)
IMC-201 (0)
IMC002 (0)
IMM2505 (0)
IMM2520 (0)
ISB 1442 (0)
JMT601 (0)
KJ-101 (0)
LB101 (0)
NI-1801 (0)
NI-2601 (0)
PF-07257876 (0)
PT886 (0)
SCR9168 (0)
SG1906 (0)
SG2501 (0)
SL-172154 (0)
TG-1801 (0)
ZL-1201 (0)
anti-CD47 monoclonal antibody (0)
IBI188 (0)
TTI-622 (0)
PF-07901800 (0)
IBI-322 (0)
IMM01 (0)
›
Associations
(8)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
ONO-7913
Sensitive: B - Late Trials
ONO-7913
Sensitive
:
B
ONO-7913
Sensitive: B - Late Trials
ONO-7913
Sensitive
:
B
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
ONO-7913
Sensitive: B - Late Trials
ONO-7913
Sensitive
:
B
ONO-7913
Sensitive: B - Late Trials
ONO-7913
Sensitive
:
B
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
ONO-7913
Sensitive: C2 – Inclusion Criteria
ONO-7913
Sensitive
:
C2
ONO-7913
Sensitive: C2 – Inclusion Criteria
ONO-7913
Sensitive
:
C2
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
venetoclax + ONO-7913
Sensitive: C2 – Inclusion Criteria
venetoclax + ONO-7913
Sensitive
:
C2
venetoclax + ONO-7913
Sensitive: C2 – Inclusion Criteria
venetoclax + ONO-7913
Sensitive
:
C2
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
ONO-7913
Sensitive: C3 – Early Trials
ONO-7913
Sensitive
:
C3
ONO-7913
Sensitive: C3 – Early Trials
ONO-7913
Sensitive
:
C3
TP53 wild-type
Myelodysplastic Syndrome
TP53 wild-type
Myelodysplastic Syndrome
ONO-7913
Sensitive: C3 – Early Trials
ONO-7913
Sensitive
:
C3
ONO-7913
Sensitive: C3 – Early Trials
ONO-7913
Sensitive
:
C3
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
atezolizumab + ONO-7913
Sensitive: C3 – Early Trials
atezolizumab + ONO-7913
Sensitive
:
C3
atezolizumab + ONO-7913
Sensitive: C3 – Early Trials
atezolizumab + ONO-7913
Sensitive
:
C3
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + ONO-7913
Sensitive: D – Preclinical
trastuzumab + ONO-7913
Sensitive
:
D
trastuzumab + ONO-7913
Sensitive: D – Preclinical
trastuzumab + ONO-7913
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login